Bardoxolone methyl

Star0

DB05983InvestigationalSmall molecule

Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.

Mechanism: RTA 402 inhibits the activity of nuclear factor kappa-B (NF-kB) activated by tumor necrosis factor (TNF) and other inflammatory agents in a variety of cancer cells. It is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and noncancerous cells by modulating oxidative stress response pathways. As a result, the drug is toxic to cancer cells but induces protective antioxidant and anti-inflammatory responses in normal cells.
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.Curator reviewed
Formula / weight: C₃₂H₄₃NO₄ · 505.699 g/mol (avg)
Code names: NSC-713200 · RTA-402

Resolves to

Compound

UNIICEG1Q6OGU1CAS218600-53-4ChEMBLCHEMBL1762621

Structure

InChIKeyWPTTVJLTNAWYAO-KPOXMGGZSA-NSMILESCOC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2

Targets

P37231PPARGO14920IKBKBP25963NFKBIA

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

32Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bardoxolone methyl, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account